抑制期乙肝肝硬化患者肝细胞癌发生率高于治愈期丙肝肝硬化患者
该多中心回顾性研究纳入9国43中心5773例肝硬化患者,比较经治并抑制的慢性乙肝(CHB)与直接抗病毒药物治愈的慢性丙肝(CHC)的肝细胞癌(HCC)发生率。经逆概率治疗加权后,抑制期CHB的5年累积HCC发生率显著高于治愈期CHC(18.1% vs 7.4%,P<0.001),但CHB抑制≥2年者与治愈期CHC相似。
要点
- 抑制期乙肝肝硬化的5年HCC累积发生率显著高于治愈期丙肝肝硬化。
- 乙肝病毒抑制不足2年者HCC风险显著升高,抑制≥2年后风险与治愈丙肝相似。
- 提示乙肝肝硬化患者应尽早治疗并维持病毒抑制以降低HCC风险。
核心结论
- 经治并抑制的乙肝肝硬化患者HCC风险仍高,但延长抑制时间可降低风险至与治愈丙肝相似水平。
研究设计与样本
- 多中心回顾性队列研究,纳入9国43中心5773例肝硬化患者,其中1877例为经治抑制的CHB,3896例为DAA治愈的CHC,采用逆概率治疗加权和Fine-Gray竞争风险分析。
主要发现
- 加权后5年累积HCC发生率抑制期CHB为18.1%,治愈期CHC为7.4%,差异显著(P<0.001)。
- 亚组分析中,性别和MELD分层(均P<0.021)、快速CHB应答者(治疗至病毒抑制<1年,P<0.001)及CHB抑制<2年者(P<0.001)HCC风险均显著高于治愈期CHC。
- CHB抑制≥2年者HCC发生率与治愈期CHC相似(P=0.954)。
- 多变量分析中,CHB抑制<2年相比治愈期CHC的亚分布风险比为20.92(P<0.001),总胆红素的亚分布风险比为0.71(P=0.04)。
关键数值与推荐
- 5年累积HCC发生率:抑制期CHB 18.1% vs 治愈期CHC 7.4%(P<0.001)。
- CHB抑制<2年 vs 治愈期CHC的亚分布风险比20.92(P<0.001)。
- 总胆红素亚分布风险比0.71(P=0.04)。
临床怎么用
- 对乙肝肝硬化患者应尽早启动抗病毒治疗并维持病毒抑制,尤其关注抑制不足2年者的HCC监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Direct-acting antiviral agents effectively cure chronic hepatitis C (CHC), whereas curative therapy for chronic hepatitis B (CHB) is rare. We aimed to compare hepatocellular carcinoma (HCC) incidence between suppressed CHB vs cured CHC patients with cirrhosis. METHODS: We analyzed 5,773 cirrhosis patients from 43 centers in 9 countries: 1,877 with treated and suppressed CHB and 3,896 with direct-acting antiviral agents-cured CHC using inverse probability treatment weight and competing risk analysis through Fine and Gray method. RESULTS: After inverse probability treatment weight (on age, sex, ethnicity, study location, albumin, total bilirubin, creatinine, platelet, tobacco use, alcohol use, diabetes mellitus, hypertension, hyperlipidemia, cardiovascular disease, steatotic liver disease, obesity, and follow-up years), 2 study groups became similar in relevant characteristics. The 5-year cumulative HCC incidence was significantly higher in suppressed CHB compared with cured CHC (18.1% vs 7.4%, P < 0.001) with consistent findings in subgroups by sex and Model for End-Stage Liver Disease (all P < 0.021), fast CHB responders (time from treatment to viral suppression <1 year) ( P < 0.001), and CHB suppressed for <2 years ( P < 0.001), but not among CHB suppressed for ≥2 years whose HCC incidence was similar to those of cured CHC ( P = 0.954). On multivariable analysis, CHB suppression <2 years as compared with cured CHC (subdistribution hazard ratio 20.92, P < 0.001) and total bilirubin (subdistribution hazard ratio 0.71, P = 0.04) were associated with higher HCC risk. DISCUSSION: HCC risk remains high in both treated and suppressed CHB cirrhosis and cured CHC cirrhosis. However, with prolonged CHB suppression, risk of HCC can be reduced, highlighting benefits of early treatment and viral suppression in patients with CHB.
引用
- Park J, Tran S, Ogawa E, et al. Higher Incidence of Hepatocellular Carcinoma in Suppressed Hepatitis B Cirrhosis Compared With Cured Hepatitis C Cirrhosis. Am J Gastroenterol. 2026. PMID: 42289090. doi:10.14309/ajg.0000000000004071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。